CSPC Pharmaceutical Group Ltd
01093
Company Profile
Business description
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C and antibiotics.
Contact
No.896 Zhongshandong Street
Gaoxin District
Hebei Province
Shijiazhuang050035
CHNT: +86 31187037015
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
19,266
Stocks News & Analysis
stocks
ASX share plunges due to Iran related weakness
Despite headwinds our long-term outlook is unchanged.
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
stocks
Revenue growth on track for undervalued ASX healthcare stock
Near-term cost growth does not change our long-term view.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.80 | 34.00 | 0.37% |
| CAC 40 | 8,259.60 | 13.81 | 0.17% |
| DAX 40 | 23,803.95 | 3.04 | -0.01% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,600.53 | 2.95 | -0.03% |
| HKSE | 25,893.54 | 141.14 | 0.55% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,924.11 | 1,028.79 | 1.84% |
| NZX 50 Index | 13,078.50 | 102.94 | -0.78% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,960.60 | 36.20 | 0.41% |
| SSE Composite Index | 3,986.22 | 20.05 | 0.51% |